Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
US-2024376471-A1 · Nov 14, 2024 · US
Medicament for liver regeneration and for treatment of liver failure
US10188682B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10188682-B2 |
| Application number | US-201514875879-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 6, 2015 |
| Priority date | Apr 7, 2011 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treatment of liver failure and/or for the protection of hepatocytes against apoptosis and/or for the regeneration of hepatocytes, the method comprising a step of administering to a patient in need of treatment a compound, which is an inhibitor of the activity of MKK4, MKK4 being encoded by the mRNA of SEQ ID NO: 1204, wherein the compound is selected from the group consisting of the following compounds: 2. The method according to claim 1 , wherein the compound is formulated as liposomes or lipid nanoparticles. 3. The method according to claim 1 , wherein the compound is a compound having the following structure: 4. The method according to claim 1 , wherein the patient is a human patient.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
not hydrogenated in the hetero ring, e.g. isoflavones · CPC title
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Tissue, human, animal or plant cell, or virus culture apparatus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10188682B2 cover?
- The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
- Who is the assignee on this patent?
- Helmholtz Zentrum Infektionsforschung Gmbh, Medizinische Hochschule Hannover
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1137. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).